ClinicalTrials.gg
CompletedNCT04509674Updated Jan 7, 2025Results posted

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

A Phase 3 interventional study of Empagliflozin and Placebo in Myocardial Infarction, sponsored by Boehringer Ingelheim. Completed at 439 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,522
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Myocardial Infarction by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Myocardial Infarction · Boehringer Ingelheim.

Started
2020
the only one that year
Phase 3
6 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, this one is the only one that started in 2020, is one of 6 in phase 3, and was the 11th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

None of the 12 studies in Myocardial Infarction by Boehringer Ingelheim is open now. The open studies under Myocardial Infarction, anywhere →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Myocardial Infarction by Boehringer Ingelheim as a file.
02

Study summary

This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.

People who are in hospital may join the study soon after being treated for their heart attack. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. All participants continue their standard treatment. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. Empagliflozin is a medicine that helps people with type 2 diabetes to lower their blood sugar. Researchers think that empagliflozin might also help people after heart attack who are at risk for heart failure, whether or not they have diabetes.

Participants are in the study for about 1 to 2 years. During this time, there are about 4 visits inperson, 2 visits are done either by phone or by use of an mobile application. Results between the empagliflozin and placebo groups are compared. The doctors also regularly check the general health of the participants.

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Of full age of consent (according to local legislation, at least ≥ 18 years) at screening.
  2. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.
  3. Male or female patients. Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
  4. Diagnosis of spontaneous Acute Myocardial Infarction (AMI): ST-Elevation Myocardial Infarction (STEMI) or Non-ST Elevation Myocardial Infarction (NSTEMI) with randomisation to occur no later than 14 calendar days after hospital admission. For patients with an in-hospital Myocardial Infarction (MI) as qualifying event, randomization must still occur within 14 days of hospital admission.
  5. High risk of HF, defined as EITHER

    1. Symptoms (e.g. dyspnea; decreased exercise tolerance; fatigue), or signs of congestion (e.g. pulmonary rales, crackles or crepitations; elevated jugular venous pressure; congestion on chest X-ray), that require treatment (e.g. augmentation or initiation of oral diuretic therapy; i.v. diuretic therapy; i.v. vasoactive agent; mechanical intervention etc.) at any time during the hospitalization.

      OR

    2. Newly developed (LVEF) \< 45% as measured by echocardiography, ventriculography, cardiac Computer Tomography (CT), Magnetic Resonance Imaging (MRI) or radionuclide imaging during index hospitalisation.
  6. In addition at least one of the following risk factors:

    • Age > 65 years,
    • Newly developed LVEF \< 35%,
    • Prior MI (before index MI) documented in medical records,
    • Estimated (eGFR) \< 60 ml/min/1.73m2 (using Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI) formula based on creatinine from local lab at any time during index hospitalisation),
    • Atrial fibrillation (persistent or permanent ; if paroxysmal, only valid if associated with index MI),
    • Type 2 diabetes mellitus (prior or new diagnosis),
    • N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) >1,400 pg/mL for patients in sinus rhythm, >2,800 pg/mL if atrial fibrillation; Brain Natriuretic Peptide (BNP) >350 pg/mL for patients in sinus rhythm, >700 pg/mL if atrial fibrillation, measured at any time during hospitalisation,
    • Uric acid >7.5 mg/dL (>446 μmol/L), measured at any time during hospitalisation,
    • Pulmonary Artery Systolic Pressure [or right ventricular systolic pressure] >40 mmHg (non-invasive [usually obtained from clinically indicated post-MI echocardiography] or invasive, at any time during hospitalisation),
    • Patient not revascularized (and no planned revascularization) for the index MI (Includes e.g. patients where no angiography is performed, unsuccessful revascularization attempts, diffuse atherosclerosis not amenable for intervention; but does NOT include if revascularization was not performed due to nonobstructive coronary arteries),
    • 3-vessel coronary artery disease at time of index MI,
    • Diagnosis of peripheral artery disease (extracoronary vascular disease, e.g. lower extremity artery disease or carotid artery disease).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of chronic Heart Failure (HF) prior to index MI.
  2. Systolic blood pressure \< 90 mmHg at randomisation.
  3. Cardiogenic shock or use of i.v. inotropes in last 24 hours before randomisation.
  4. Coronary Artery Bypass Grafting planned at time of randomisation.
  5. Current diagnosis of Takotsubo cardiomyopathy.
  6. Any current severe (stenotic or regurgitant) valvular heart disease.
  7. \< 20 ml/min/1.73m2 (using CKD-EPI formula based on most recent creatinine from local lab during index hospitalisation) or on dialysis.
  8. Type I diabetes mellitus. Further exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,522 participants (actual)

Study arms

  • Experimental
    Empagliflozin 10 mg

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Composite of Time to First Heart Failure Hospitalisation or All-cause Mortality

    The composite of time to first heart failure hospitalization or all-cause mortality is reported as the incidence rate of the first occurrence of hospitalization for heart failure (HHF) or death, whichever is earliest. The incidence rate was calculated as: the number of patients with an event for hospitalization for heart failure or death by treatment group during time at risk divided by the total time patients were at risk in that treatment group multiplied by 100 (per 100 Pt-years, Pt as abbreviation of patient).

    Time frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

Secondary outcomes

  1. Key Secondary Endpoint - Total Number of Hospitalisations for Heart Failure (HHF) or All-cause Mortality

    The total number of hospitalisations for heart failure (HHF) or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

    Time frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

  2. Key Secondary Endpoint - Total Number of Non-elective Cardiovascular (CV) Hospitalisations or All-cause Mortality

    The total number of non-elective cardiovascular (CV) hospitalisations or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

    Time frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

  3. Key Secondary Endpoint - Total Number of Non-elective All-cause Hospitalisations or All-cause Mortality

    The total number of non-elective all-cause hospitalisations or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

    Time frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

  4. Key Secondary Endpoint - Total Number of Hospitalisations for Myocardial Infarction (MI) or All-cause Mortality

    The total number of hospitalisations for myocardial infarction (MI) or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for factors for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

    Time frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

  5. Time to Cardiovascular (CV) Mortality

    The time to cardiovascular (CV) mortality is reported as the incidence rate of cardiovascular (CV) mortality, including deaths of unknown cause. The incidence rate was calculated as: the number of patients with a cardiovascular death event by treatment group during time at risk divided by the total time patients were at risk in that treatment group multiplied by 100 (per 100 Pt-years, Pt as abbreviation of patient).

    Time frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

07

Results

Posted Jan 7, 2025

Participant flow

Streamlined, randomised, placebo-controlled, double-blind, parallel-group trial in acute myocardial infarction (MI) hospitalised patients with high-risk for subsequent hospitalization for heart failure (HHF) and mortality. Patients were randomised 1:1 to empagliflozin or placebo within 14 days of hospitalisation. Patients were treated and remained in the trial until approximately a total number of 532 patients had primary endpoint events (i.e. event driven).

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 10 mg
Started32623260
Treated32293234
Completed25132550
Not completed749710
Withdrew: Not treated3326
Withdrew: Protocol violation910
Withdrew: Lost to follow-up3139
Withdrew: Patient refusal to continue, not due to adverse event452418
Withdrew: Adverse event, serious fatal event114
Withdrew: Adverse event, non-fatal event107118
Withdrew: Other reason than listed10695

Outcome measures

PrimaryComposite of Time to First Heart Failure Hospitalisation or All-cause Mortality

The composite of time to first heart failure hospitalization or all-cause mortality is reported as the incidence rate of the first occurrence of hospitalization for heart failure (HHF) or death, whichever is earliest. The incidence rate was calculated as: the number of patients with an event for hospitalization for heart failure or death by treatment group during time at risk divided by the total time patients were at risk in that treatment group multiplied by 100 (per 100 Pt-years, Pt as abbreviation of patient).

Time frame:
From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Reported as:
Number · Pt with events/100 pt-years at risk
Composite of Time to First Heart Failure Hospitalisation or All-cause Mortality
Pt with events/100 pt-years at riskPlaceboEmpagliflozin 10 mg
Composite of Time to First Heart Failure Hospitalisation or All-cause Mortality6.58 (5.86 to 7.35)5.85 (5.17 to 6.57)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = 0.2061 (Null hypothesis: there is no difference regarding the risk of the endpoint in question between empagliflozin and placebo. p\<=0.05 required for testing of subsequent key secondary endpoint hypotheses) · Hazard ratio (hr): 0.90 · 95% CI 0.76 to 1.06Empagliflozin vs. Placebo
SecondaryKey Secondary Endpoint - Total Number of Hospitalisations for Heart Failure (HHF) or All-cause Mortality

The total number of hospitalisations for heart failure (HHF) or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

Time frame:
From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Reported as:
Number · Events/100 patient-years at risk
Key Secondary Endpoint - Total Number of Hospitalisations for Heart Failure (HHF) or All-cause Mortality
Events/100 patient-years at riskPlaceboEmpagliflozin 10 mg
Key Secondary Endpoint - Total Number of Hospitalisations for Heart Failure (HHF) or All-cause Mortality8.25 (6.92 to 9.83)7.14 (5.91 to 8.63)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Negative binomial regression · p = 0.2423 · Adjusted event rate ratio: 0.87 · 95% CI 0.68 to 1.10Empagliflozin vs. Placebo
SecondaryKey Secondary Endpoint - Total Number of Non-elective Cardiovascular (CV) Hospitalisations or All-cause Mortality

The total number of non-elective cardiovascular (CV) hospitalisations or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

Time frame:
From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Reported as:
Number · Events/100 patient-years at risk
Key Secondary Endpoint - Total Number of Non-elective Cardiovascular (CV) Hospitalisations or All-cause Mortality
Events/100 patient-years at riskPlaceboEmpagliflozin 10 mg
Key Secondary Endpoint - Total Number of Non-elective Cardiovascular (CV) Hospitalisations or All-cause Mortality16.90 (15.10 to 18.92)15.52 (13.82 to 17.43)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Negative binomial regression · p = 0.2867 · Adjusted event rate ratio: 0.92 · 95% CI 0.78 to 1.07Empagliflozin vs. Placebo
SecondaryKey Secondary Endpoint - Total Number of Non-elective All-cause Hospitalisations or All-cause Mortality

The total number of non-elective all-cause hospitalisations or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

Time frame:
From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Reported as:
Number · Events/100 patient-years at risk
Key Secondary Endpoint - Total Number of Non-elective All-cause Hospitalisations or All-cause Mortality
Events/100 patient-years at riskPlaceboEmpagliflozin 10 mg
Key Secondary Endpoint - Total Number of Non-elective All-cause Hospitalisations or All-cause Mortality26.28 (23.92 to 28.87)22.96 (20.84 to 25.31)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Negative binomial regression · p = 0.0463 · Adjusted event rate ratio: 0.87 · 95% CI 0.7654 to 0.9978Empagliflozin vs. Placebo
SecondaryKey Secondary Endpoint - Total Number of Hospitalisations for Myocardial Infarction (MI) or All-cause Mortality

The total number of hospitalisations for myocardial infarction (MI) or all-cause mortality is reported using the adjusted event rate. The adjusted event rate is based on a negative binomial model adjusted for factors for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

Time frame:
From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Reported as:
Number · Events/100 patient-years at risk
Key Secondary Endpoint - Total Number of Hospitalisations for Myocardial Infarction (MI) or All-cause Mortality
Events/100 patient-years at riskPlaceboEmpagliflozin 10 mg
Key Secondary Endpoint - Total Number of Hospitalisations for Myocardial Infarction (MI) or All-cause Mortality6.27 (5.19 to 7.58)6.66 (5.49 to 8.08)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Negative binomial regression · p = 0.6311 · Adjusted event rate ratio: 1.06 · 95% CI 0.83 to 1.35Empagliflozin vs. Placebo
SecondaryTime to Cardiovascular (CV) Mortality

The time to cardiovascular (CV) mortality is reported as the incidence rate of cardiovascular (CV) mortality, including deaths of unknown cause. The incidence rate was calculated as: the number of patients with a cardiovascular death event by treatment group during time at risk divided by the total time patients were at risk in that treatment group multiplied by 100 (per 100 Pt-years, Pt as abbreviation of patient).

Time frame:
From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Reported as:
Number · Pt with events/100 pt-years at risk
Time to Cardiovascular (CV) Mortality
Pt with events/100 pt-years at riskPlaceboEmpagliflozin 10 mg
Time to Cardiovascular (CV) Mortality2.76 (2.31 to 3.25)2.78 (2.33 to 3.28)
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Cox · p = 0.8124 · Hazard ratio (hr): 1.03 · 95% CI 0.81 to 1.31Empagliflozin vs. Placebo

Adverse events

Collected over All-cause mortality - From first drug administration until individual day of trial completion. Up to 1004 days. Adverse event reporting - From first study drug administration to last study drug administration plus 7 days (residual effect period). Up to 1004 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo178/3,262 (5.5%)798/3,229 (24.7%)0/3,229 (0%)
Empagliflozin 10 mg169/3,260 (5.2%)765/3,234 (23.7%)0/3,234 (0%)
Most frequent serious events
Showing 10 of 490
Most frequent serious events
EventPlaceboEmpagliflozin 10 mg
Cardiac failureCardiac disorders230/3229159/3234
Myocardial infarctionCardiac disorders94/3229110/3234
Angina unstableCardiac disorders54/322952/3234
Acute kidney injuryRenal and urinary disorders43/322927/3234
PneumoniaInfections and infestations30/322931/3234
Angina pectorisCardiac disorders28/322930/3234
Gastrointestinal haemorrhageGastrointestinal disorders22/322928/3234
Non-cardiac chest painGeneral disorders27/322928/3234
COVID-19Infections and infestations25/322920/3234
Ventricular tachycardiaCardiac disorders22/322918/3234

Baseline characteristics

Randomised set (RS): All randomised patients, whether treated or not.

Age, Continuous
Age, Continuous(Years)PlaceboEmpagliflozin 10 mgTotal
Mean63.7 ± 10.863.6 ± 11.063.6 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 10 mgTotal
Female8138121625
Male244924484897
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEmpagliflozin 10 mgTotal
Hispanic or Latino331338669
Not Hispanic or Latino285928665725
Unknown or Not Reported7256128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEmpagliflozin 10 mgTotal
White272127305451
Black/African-American484492
Asian413421834
Other, including mixed race7916
Missing7356129
08

Study locations

439 sites
  • Advanced Cardiovascular LLC
    Alexander City, Alabama 35010, United States
  • Grandview Medical Center
    Birmingham, Alabama 35243, United States
  • Heart Center Research, LLC
    Huntsville, Alabama 35801, United States
  • Mercy Gilbert Medical Center
    Gilbert, Arizona 85297, United States
  • Arkansas Cardiology, PA
    Little Rock, Arkansas 72205, United States
  • Comprehensive Cardiovascular Medical Group
    Bakersfield, California 93309, United States
  • Valley Clinical Trials, Inc.
    Covina, California 91723, United States
  • Cardiovascular Innovation and Research Center
    Long Beach, California 90813, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • InvivoCure
    Mission Hills, California 91346, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Valley Clinical Trials, Inc.
    Pasadena, California 91105, United States
  • Kaiser Permanente
    San Diego, California 92123, United States
  • San Diego Cardiac Center
    San Diego, California 92123, United States
  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Interventional Cardiology Medical Group
    West Hills, California 91307, United States
  • George Washington University Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Clearwater Cardiovascular Consultants
    Clearwater, Florida 33756, United States
  • Integrative Research Associates
    Fort Lauderdale, Florida 33312, United States
  • University of Florida Health Jacksonville
    Jacksonville, Florida 32209, United States
  • Cardiology Partners Clinical Research Institute
    Palm Beach Gardens, Florida 33410, United States
  • Charlotte Heart Group Research Center
    Port Charlotte, Florida 33952, United States
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
  • Cardiovascular Consultants of South Georgia, LLC
    Thomasville, Georgia 31792, United States
  • Atlanta Heart Specialists, LLC
    Tucker, Georgia 30084, United States
  • Advanced Heart Care, LLC, Medicoricum, LLC
    Fairview Heights, Illinois 62208, United States
  • Midwest Cardiovascular Research and Education Foundation
    Elkhart, Indiana 46514, United States
  • Cardiovascular Research of Northwest Indiana, LLC
    Munster, Indiana 46321, United States
  • Reid Physician Associates
    Richmond, Indiana 47374, United States
  • Midwest Heart and Vascular Specialists
    Overland Park, Kansas 66211, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536-0200, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Eastern Maine Medical Center
    Bangor, Maine 04401, United States
  • Cardiovascular Specialists of Central Maryland
    Columbia, Maryland 21044, United States
  • Shady Grove Adventist Hospital
    Rockville, Maryland 20850, United States
  • Healthy Heart Cardiology
    Grand Rapids, Michigan 49546, United States
  • Western Michigan University
    Kalamazoo, Michigan 49009, United States
  • Mid Michigan Medical Center
    Midland, Michigan 48670, United States
  • Michigan Heart, PC
    Ypsilanti, Michigan 48197, United States
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
  • Cardiology Associates Research, LLC
    Tupelo, Mississippi 38801, United States
  • Missouri Cardiovascular Specialists, LLP
    Columbia, Missouri 65201, United States
  • University of Missouri Health System
    Columbia, Missouri 65212, United States
  • North Kansas City Hospital
    North Kansas City, Missouri 64116, United States
  • Gateway Cardiology, PC
    Saint Louis, Missouri 63128, United States
  • St. Louis Heart and Vascular, P.C.
    Saint Louis, Missouri 63136, United States
  • Holy Name Medical Center
    Hackensack, New Jersey 07601, United States
  • AtlantiCare
    Pomona, New Jersey 08240, United States
  • The Heart House
    Vineland, New Jersey 08360, United States
  • SJH Cardiology Associates
    Liverpool, New York 13088, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27517, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Moses H. Cone Memorial Hospital
    Greensboro, North Carolina 27401, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27405, United States
  • North Carolina Heart and Vascular
    Raleigh, North Carolina 27607, United States
  • Trinity Health Center Medical Arts
    Minot, North Dakota 58701, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • Cincinnati VA Medical Center
    Cincinnati, Ohio 45220, United States
  • Kettering Medical Center
    Kettering, Ohio 45429, United States
  • Oklahoma Heart Hospital Research Foundation, Incorporated
    Oklahoma City, Oklahoma 73120, United States
  • South Oklahoma Heart Research Group
    Oklahoma City, Oklahoma 73135, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Guthrie Medical Group PC
    Sayre, Pennsylvania 18840, United States
  • Upstate Cardiology, PA
    Greenville, South Carolina 29607, United States
  • Carolina Heart Specialists, LLC
    Lancaster, South Carolina 29720, United States
  • Monument Health
    Rapid City, South Dakota 57701, United States
  • Centennial Heart Cardiovascular Consultants, LLC
    Nashville, Tennessee 37203, United States
  • Parkway Cardiology Associates
    Oak Ridge, Tennessee 37830, United States
  • Cardiovascular Research of Knoxville
    Powell, Tennessee 37849, United States
  • Texas Health Presbyterian Hospital Allen
    Allen, Texas 75013, United States
  • Amarillo Heart Clinical Research Institute, Incorporated
    Amarillo, Texas 79106, United States
  • Pharmatex Research
    Amarillo, Texas 79109, United States
  • Dallas VA Medical Center
    Dallas, Texas 75216, United States
  • Baylor Scott and White Health
    Plano, Texas 75093, United States
  • South Texas Cardiovascular Consultants
    San Antonio, Texas 78201, United States
  • Revival Research Institute, LLC.
    Sherman, Texas 75092, United States
  • Cardiovascular Associates of East Texas, PA
    Tyler, Texas 75701, United States
  • Carient Heart and Vascular
    Manassas, Virginia 20109, United States
  • Riverside Regional Medical Center
    Newport News, Virginia 23601, United States
  • Tidewater Physicians Multispecialty Group
    Newport News, Virginia 23606, United States
  • Sentara Hospitals
    Norfolk, Virginia 23507, United States
  • Roanoke Heart Institute PLC
    Roanoke, Virginia 24014, United States
  • Instituto Cardiovascular de Buenos Aires
    Belgrano, C1428ART, Argentina
  • Fundacion Sanatorio Güemes
    Ciudad Autonoma Buenos Aires, C1180 AAX, Argentina
  • Hospital Italiano de Córdoba
    Cordoba, X5000, Argentina
  • Sanatorio Allende
    Cordoba, X5000, Argentina
  • Centro Medico Luquez
    Cordoba, X5006CBI, Argentina
  • Hospital Privado Centro Medico de Cordoba
    Cordoba, X5016KEH, Argentina
  • Clinica Privada del Prado
    Cordoba, X5020AAA, Argentina
  • Centro de Investigacion Clinica Coronel Suarez
    Coronel Suarez, B7540GHD, Argentina
  • Instituto de Cardiologia de Corrientes
    Corrientes, 3400, Argentina
  • Fundación Favaloro para la Docencia e Investigación Medica
    Monserrat, C1093AAS, Argentina
  • Sanatorio Modelo de Quilmes
    Quilmes, B1878GEG, Argentina
  • Instituto Cardiovascular de Rosario
    Rosario, S2000, Argentina
  • Sanatorio Delta
    Rosario, S2000, Argentina
  • Sanatorio Parque
    Rosario, S2000, Argentina
  • Corporacion Medica de Gral. San Martin S.A.
    San Martin, B1650CSP, Argentina

Showing the first 100 of 439 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Nov 2023, 34 months.

Results were first posted in Jan 2025, 1 year 2 months after primary completion.

Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2020
First posted
Aug 12, 2020
StartActual
Dec 16, 2020
Primary completionActual
Nov 5, 2023
CompletionActual
Nov 5, 2023
Results first posted
Jan 7, 2025
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04509674
Responsible party
Sponsor
First posted
Aug 12, 2020
Start date
Dec 16, 2020
Primary completion
Nov 5, 2023
Completion
Nov 5, 2023
Results posted
Jan 7, 2025
Last update
Jan 7, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion